| SEC For | rm 4 | | | | | | | | | | | | | | | | |
|--|---|------------------------------------|--|--------------|--|--|---|--|--------------------|---|-------------------------------------|---|---|---|--|---------------------------------------|--|
| FORM 4 | | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | | | | OMB APPROVAL | | | |
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | | | | | Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | | | | | | | HIP | Estim | Numbe ated av per res | erage burde | 3235-0287 n 0.5 | |
| 1. Name and Address of Reporting Person [*] Stuart Bryan | | | | | 2. Issuer Name and Ticker or Trading Symbol <u>Fulcrum Therapeutics</u> , Inc. [FULC] | | | | | | | elationship o eck all applic Director | able) | g Pers | on(s) to Iss 10% O Other (: | vner | |
| | ` | First) HERAPEUTICS, E STREET | (Middle) INC. | | 3. Date of Earliest Transaction (Month/Day/Year) 01/25/2021 | | | | | | | X Officer (give title Other (specify below) below) Chief Operating Officer | | | | speeny | |
| (Street) CAMBRIDGE MA | | | 02139 | 4 | 4. If Amendment, Date of Original Filed (Month/Day/Year | | | | | ay/Year) | Line | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) (State) (Zip) | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Trans. Date | | | | 2. Transacti | action 2A. Deemed Execution Date, | | 3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 8) | | red (A) or | or 5. Amount | | Form (D) or | n: Direct I r Indirect I Istr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | | | | | Code V | Amount | (A) o (D) | Price | Transacti (Instr. 3 a | on(s) | | | (11011.4) | |
| | | | Table II - D (e | | | | | uired, Dis s, options | | | | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | | 3A. Deemed Execution Dat if any (Month/Day/Ye | Code | action (Instr. | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number derivativ Securitie Beneficia Owned Followin Reported Transact | re es ally g | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | unt (ber | (Instr. 4) | | | | |
| Stock Option (right to buy) | \$13.09 | 01/25/2021 | | А | | 134,376 | | (1) | 01/24/2031 | Common Stock | 134,376 | \$0.00 | 134,3 | 76 | D | | |

Explanation of Responses:

1. This option was granted on January 25, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2021, subject to continued service. **Remarks:**

/s/ Peter Thomson, as attorney-01/27/2021

in-fact for Bryan Stuart ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.